This webinar introduced the importance of bioanalysis and its downstream effects on clinical development and clinical pharmacology.
David Lowis described a case study where D360 was used to replace older technologies at a biotechnology company. He also showed D360’s new visualization tools and shares the future roadmap as D360 advances its support of biologics in addition to small molecules.
Infants face a gap in protection against influenza between birth and the time of vaccination. Thus, maternal immunization is the only way to prevent flu infection in pregnant women and newborns. Our current understanding of the optimal timing of vaccination is rudimentary. Watch this webinar with Dr. Michael Dodds to learn how modeling and simulation (M&S) offers an alternate approach to dedicated clinical studies to determine the best time to vaccine pregnant women against influenza.
Making Sense of 6MWT Variability: Developing a Disease Progression Model for Duchenne Muscular Dystrophy
Watch this webinar with Drs. Lora Hamuro and Joga Gobburu to learn how they developed a natural history progression model for DMD using the 6MWT.
In this webinar, Dr. Tom Polasek, a clinical pharmacologist at Certara Strategic Consulting, explained how he used the Simcyp Simulator to predict olanzapine exposure in individual patients. By watching this webinar you will learn how PBPK modeling and simulation technology can be re-purposed to support model-informed precision dosing.
Watch this webinar to learn how the delay operator implemented in Phoenix 8 can eliminate the need to add complex lines of code for each delay differential equation, simplify modeling delayed outcomes, and avoid inefficient workarounds and approximations.
Watch this webinar with Dr. Graham Scott, Senior Director of Clinical Pharmacology at Certara Strategic Consulting, to learn why you should invest in “apocalyptic clinical pharmacology.” Dr. Scott presented case studies that illustrate how sponsors can benefit from a clinical pharmacology strategy that uses model-informed approaches to inform and “fill in the gaps” of clinical trials.
Watch this webinar with Cen Guo—a graduate student at UNC-Chapel Hill—to learn how she used an integrated approach to predict alterations in bile acid disposition due to inhibition of multiple transporters using the model bile acid taurocholate (TCA).
MBMA helps sponsors design less costly and more precise trials with an eye toward achieving commercial success for both the drug and portfolio. Watch this webinar with Dr. Mark Lovern, Vice President at Certara Strategic Consulting, to learn how leveraging public data can provide value by abbreviating the “cash spiral” inherent to proprietary data.
In this webinar, Professor Jean-Michel Cardot explained how to perform Level C IVIVC using Phoenix. Learn how to calculate pharmacokinetic parameters via the non-compartmental analysis module; how to calculate dissolution parameters via the dissolution module; how to link the in vivo pharmacokinetic parameters and in vitro dissolution parameters via the linear relationship module; and how to calculate dissolution limits.